Home
Global Supplier Directory
APPLIANCE Engineer
Supplier Solutions
APPLIANCE Line
Whitepaper Library
Calendar of Events
Association Locator
Contents Pages
Market Research
Subscription Center


 
Daily News

Boston Scientific Announces 2003 Q4 Results
Feb 3, 2004
 Printable format
 Email this Article
 Search

Medical-device maker Boston Scientific Corp. (Natick, MA, U.S.) has announced its 2003 fourth-quarter results. The company had net income of U.S. $137 million, or $0.16 a share, for the latest quarter, up from $105 million, or $0.12 a share, a year earlier.

The per-share earnings figures reflect a 2-for-1 stock split that took effect in November 2003.

Excluding $4 million in unspecified charges, the company said it would have posted earnings of $141 million, or $0.17 a share, up from $130 million, or $0.15 a share, a year ago.

Analysts surveyed by Thomson First Call were expecting the company to report fourth-quarter earnings, excluding items, of $0.16 a share.

Sales for the latest quarter rose 15 percent to $939 million from $814 million.

International sales jumped 46 percent to $457 million amid a 58 percent surge in European sales. This fourth-quarter surge in profit is being attributed to sales of stents in Europe and other overseas markets. Stents are tiny metal scaffolds used to prop open arteries after they have been unclogged by a procedure known as balloon angioplasty.

In the United States, sales slipped 3.6 percent to $482 million.

In November, Boston Scientific's drug-coated Taxus stent won unanimous backing from a Food and Drug Administration advisory panel, moving it closer to competition with a rival Johnson & Johnson device already on the market.

Taxus and Johnson & Johnson's Cypher are the first of a new generation of the devices that are coated with drugs aimed at preventing arteries from reclogging following angioplasty.

Johnson & Johnson's stent went on sale last April in the United States, where it has gained the bulk of a $2 billion U.S. market. By 2007, analysts estimate the U.S. market for drug-coated stents will rise to about $4.4 billion.

For all of 2003, Boston Scientific had net income of $472 million, or 56 cents a share, up 27 percent from $373 million, or 45 cents a share, in 2002. Sales increased 19 percent to $3.48 billion from $2.92 billion. (AFP)

Back to Daily News

 

Daily News

...........................................................

Oct 30, 2014: Whirlpool Corp. reports strong third-quarter

Oct 30, 2014: Statistical Portrait of the European Appliance Industry Released by Appliance Magazine

Oct 30, 2014: New Whirlpool acquisition Indesit reports profit for year so far

Oct 30, 2014: Consumer Confidence Index rebounds in October

Oct 29, 2014: New home sales up slightly in September 2014

More Daily News>>

RSS Feeds
.........................................................
Appliance Industry
Market Research

...........................................................

October 2014: Portrait of the European Appliance Industry
September 2014: Appliance Industry Focus: HVAC
June 2014: Appliance Magazine Market Insight: April 2014
May 2014: Appliance Magazine Market Insight: March 2014




 
Contact Us | About Us | Subscriptions | Advertising | Home
UBM Canon © 2014  

Please visit these other UBM Canon sites

UBM Canon Corporate | Design News | Test & Measurement World | Packaging Digest | EDN | Qmed | Plastics Today | Powder Bulk Solids | Canon Trade Shows